Hopkins tests drug switch to stop MS symptoms from creeping back

This small pilot study explores whether switching from the MS medication ocrelizumab to a similar drug called ublituximab can help patients who experience a 'wearing off' effect, where their MS symptoms return or worsen in the weeks before their next scheduled infusion. The study will enroll 50 adults with relapsing MS who are already on ocrelizumab and are noticing this pattern. Researchers will track changes in symptoms like fatigue and mobility to see if the switch provides better, more consistent control of the disease.